Leading indicators This is setting up nicely for Sirona shareholders. New clinical trial on extra strength 1067 with one of the major pharmaceuticals in the world is very likely going to draw significant investor interest here folks. That in combination with the public and formal declaration that our product hits the market (this week?) means that the dirt cheap stock price will be a thing of the past, never to be obtained ever again. This company continues to surprise me lately, specifically with today's announcement. I think if they were to announce a definitive deal for sglt2 that would put us in significantly higher valuations. If we get to well over a buck USD before end of November, that wouldn't surprise me in the least.